Mednet Logo
CommunityRadiation Oncology

How would you counsel a patient concerned about receiving IMRT rather than IMPT for oropharyngeal cancer?

A recent randomized trial showed equivalent rates of disease control, with an "unexpected improvement in survival outcomes" with IMPT per the authors' discussion. Of course, the survival difference is a more sensational topic for the media. Given the small event numbers and significant crossover in the trial, how would you reassure concerned patients that IMPT is "a" standard of care rather than "the" standard of care, and that their IMRT treatment is appropriate?
7 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on

I would tell the patient there is absolutely no concern at all with IMRT, and it is a very well-established SOC. I am personally unclear about the OS benefit with IMPT, as it was pointed out, unexpected. It is unusual to see no difference in PFS and no tox difference, and yet there is an OS differen...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Princess Margaret Cancer Centre
Answered on

I would inform the patient that IMRT remains a well-established standard of care and is my first choice for definitive radiotherapy for oropharyngeal cancer. The reported survival difference in that trial was based on very few events and occurred in a study with significant crossover, as well as an ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Genesis Healthcare Partners- San Diego
Answered on

Treatment at a center of excellence with high volumes and/or a well-trained, experienced radiation oncologist and team is more important than proton or photon discussion, IMHO.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Texas MD Anderson Cancer Center
Answered on

The question essentially contains the desired answer. Further, given limited media awareness, I think a true survival difference would be of interest to oncologists in general.

The question phrasing is interesting, as the conclusion of Frank et al., PMID 41391462 was that IMPT is "a standard..." and ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Medical University of South Carolina (Charleston)
Answered on

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Henry Ford Health System
Answered on

I agree with the responses provided by @Dr. First Last and @Dr. First Last. The most critical determinant of success in these complex patients is timely work-up, proper staging and treatment in a high-volume center with experienced head and neck radiation oncologists and a multidisciplinary team inc...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Baylor Scott & White Health
Answered on

I would tell the patient that the investigators themselves did not have a clear biologic explanation for the survival difference they observed, since the cancer control rates were otherwise very similar between groups and the absolute number of treatment-related deaths was small: only 9 across both ...

Join for free or sign in to see the full answer